Table 3 Management, Complication and Follow-up

Ngendaho et al. [7]

Glans: 46.7%

Partial Penectomy: 80%

Total Penectomy:13.3%

Penectomy + ILND:33.3%

N/A

SSI:10%; Lymphocele:10%, Skin necrosis, Death, Meatal stenosis

0% recurrence at 6 months

Diallo et al. [8]

Glans: 33.3%

Glans + Penile Shaft: 66.7%

PP: 16.7%

TP + ILND: 16.7%

Emasculation:16.7%

Decline Treatment:33.3%

N/A

N/A

50% Loss to follow-up

1-year mortality 33.3%

Magoha et al. [9]

Glans: 43.6%

Glans + Penile Shaft: 21.8%

Prepuce: 12.7%

Circumcision: 3.6%

Local Excision + Rad: 7.2%

PP + Rad: 20.1%

PP + Chemo: 5.5%

PP + Chemo + rad: 10.9%

TP + Rad: 14.5%

Rad alone: 9.1%

Chemo + Rad: 10.9%

N/A

N/A

Gueye et al. [11]

Glans: 36.4%

Glans + Shaft: 45.5%

Partial Penectomy: 18.2%

Total Penectomy: 9.1%

Decline Treatment: 72.7%

N/A

N/A

100% Loss to Follow-up

Ajekigbe et al [12]

Penile Shaft: 42.9%

N/A

N/A

N/A

N/A

Sow et al. [13]

Glans: 62.5%%

Shaft: 12.5%

Prepuce: 25%

TP: 37.5%

Emasculation + ILND:12.5%

N/A

N/A

Loss to follow-up: 50%

Abdulkadir et al. [14]

Glans: 50%

Glans + Prepuce:33.3%

Shaft: 16.7%

Chayla et al. [15]

Glans: 60.1%

Glans + Shaft: 13.6%

Prepuce: 7.6%

Partial penectomy: 63.1%

Total Penectomy:10.8%

ILND: 16.8%

Penile sparing: 9.3%

Chemo: 5.9%

Rad: 5.1%

SSI: 44.8%;

DVT: 15.5%

Chronic Pain: 13.8%

Scrotal edema: 10.3%

76.1% loss to follow-up at 5 years

Mortality:10%

Recurrence: 5.3%

Sow et al. [16]

Glans: 12.5%

Glans + Shaft: 62.5%

Shaft: 25%

Partial Penectomy: 62.5%

TP + ILND: 12.5%

Decline Treatment: 25%

25% loss to follow-up

Recurrence: 12.5%

Death: 12.5%